Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Florence, Italy, and online, on 30 March-2 April, 2025. This meeting brought together clinicians, researchers, nurses, and patients to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.

EBMT 2025

The 51st Annual Meeting of the EBMT
30 Mar–02 April 2025 | Florence, Italy

EBMT 2025

The 51st Annual Meeting of the EBMT
30 Mar–02 April 2025 | Florence, Italy
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Florence, Italy, and online, on 30 March-2 April, 2025. This meeting brought together clinicians, researchers, nurses, and patients to discuss the latest updates in the field of blood and marrow transplantation and cellular therapies.
View all videos

Recent videos

View all videos
1:23
The potential of improving post-transplant outcomes with cytokine-activated NK-cells
Rémy Duléry • 1 Apr 2025
3:49
Tackling the challenges with generating “off-the-shelf” allogeneic T-cell & NK-cell products
Rizwan Romee • 4 May 2025
2:06
The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
Evelyn Ullrich • 11 Apr 2025
2:36
Assessing the eligibility of older patients for transplant or cellular therapy
Parastoo Dahi • 22 Apr 2025

Transplantation

View all
1:23
The potential of improving post-transplant outcomes with cytokine-activated NK-cells
Rémy Duléry • 1 Apr 2025
2:36
Assessing the eligibility of older patients for transplant or cellular therapy
Parastoo Dahi • 22 Apr 2025

CAR-T & Cellular Therapy

View all
1:23
The potential of improving post-transplant outcomes with cytokine-activated NK-cells
Rémy Duléry • 1 Apr 2025
3:49
Tackling the challenges with generating “off-the-shelf” allogeneic T-cell & NK-cell products
Rizwan Romee • 4 May 2025

Leukemia

View all
2:06
The CAR FACTORY network: developing genetically optimized CAR-T and CAR-NK cellular therapies
Evelyn Ullrich • 11 Apr 2025
3:47
The risk of myelopathy following CAR-T and managing this rare complication
Parastoo Dahi • 22 Apr 2025

Lymphoma

View all
2:36
Assessing the eligibility of older patients for transplant or cellular therapy
Parastoo Dahi • 22 Apr 2025
3:47
The risk of myelopathy following CAR-T and managing this rare complication
Parastoo Dahi • 22 Apr 2025

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals